Yaws

Br Med Bull. 2015;113(1):91-100. doi: 10.1093/bmb/ldu037. Epub 2014 Dec 18.

Abstract

Introduction: Yaws, caused by Treponema pallidum ssp. pertenue, is endemic in parts of West Africa, Southeast Asia and the Pacific. The WHO has launched a campaign based on mass treatment with azithromycin, to eradicate yaws by 2020.

Sources of data: We reviewed published data, surveillance data and data presented at yaws eradication meetings.

Areas of agreement: Azithromycin is now the preferred agent for treating yaws. Point-of-care tests have demonstrated their value in yaws.

Areas of controversy: There is limited data from 76 countries, which previously reported yaws. Different doses of azithromycin are used in community mass treatment for yaws and trachoma.

Growing points: Yaws eradication appears an achievable goal. The programme will require considerable support from partners across health and development sectors.

Areas timely for developing research: Studies to complete baseline mapping, integrate diagnostic tests into surveillance and assess the impact of community mass treatment with azithromycin are ongoing.

Keywords: eradication; neglected tropical diseases; syphilis; yaws.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / economics
  • Azithromycin / administration & dosage*
  • Azithromycin / economics
  • Cost-Benefit Analysis
  • Disease Eradication* / economics
  • Disease Eradication* / methods
  • Humans
  • Program Development
  • Sentinel Surveillance
  • Treponema pallidum / drug effects*
  • Yaws* / drug therapy
  • Yaws* / epidemiology
  • Yaws* / prevention & control

Substances

  • Anti-Bacterial Agents
  • Azithromycin